MX2021004225A - Metodos para tratar distrofia muscular oculofaringea (dmof). - Google Patents
Metodos para tratar distrofia muscular oculofaringea (dmof).Info
- Publication number
- MX2021004225A MX2021004225A MX2021004225A MX2021004225A MX2021004225A MX 2021004225 A MX2021004225 A MX 2021004225A MX 2021004225 A MX2021004225 A MX 2021004225A MX 2021004225 A MX2021004225 A MX 2021004225A MX 2021004225 A MX2021004225 A MX 2021004225A
- Authority
- MX
- Mexico
- Prior art keywords
- opmd
- methods
- reagents
- muscular dystrophy
- oculopharyngeal muscular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente descripción se refiere a métodos para administrar un constructo de terapia génica que comprende reactivos de interferencia de ARN (ARNi), tal como microARN de horquilla corta (shmiR), en combinación con reactivos de reemplazo PABPN1, tal como polinucleótidos que codifican la proteína PABPN1 funcional los cuales no son el objetivo de los reactivos de ARNi, para el tratamiento de distrofia muscular oculofaríngea (DMOF) en individuos que padecen DMOF o que están predispuestos a la misma. En ciertos aspectos, el método comprende la inyección directa a los músculos faríngeos de un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862747089P | 2018-10-17 | 2018-10-17 | |
PCT/AU2019/051134 WO2020077412A1 (en) | 2018-10-17 | 2019-10-17 | Methods for treating oculopharyngeal muscular dystrophy (opmd) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004225A true MX2021004225A (es) | 2021-05-27 |
Family
ID=70282838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004225A MX2021004225A (es) | 2018-10-17 | 2019-10-17 | Metodos para tratar distrofia muscular oculofaringea (dmof). |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220106594A1 (es) |
EP (1) | EP3866859A4 (es) |
JP (1) | JP2022508835A (es) |
KR (1) | KR20210081361A (es) |
CN (1) | CN112867511A (es) |
AU (1) | AU2019362925A1 (es) |
BR (1) | BR112021007256A2 (es) |
CA (1) | CA3114945A1 (es) |
IL (1) | IL282323A (es) |
MX (1) | MX2021004225A (es) |
SG (1) | SG11202102185RA (es) |
WO (1) | WO2020077412A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115838725B (zh) * | 2022-12-30 | 2023-09-08 | 广州派真生物技术有限公司 | 在哺乳动物心脏中特异性启动基因的启动子序列及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014117050A2 (en) * | 2013-01-26 | 2014-07-31 | Mirimus, Inc. | Modified mirna as a scaffold for shrna |
CA3020754C (en) * | 2016-04-14 | 2023-07-25 | Benitec Biopharma Limited | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
MX2019007110A (es) * | 2016-12-14 | 2019-12-05 | Benitec Biopharma Ltd | Reactivos para el tratamiento de la distrofia muscular oculofaringea (opmd) y uso de estos. |
WO2020172720A1 (en) * | 2019-02-28 | 2020-09-03 | Benitec Biopharma Limited | Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd) |
-
2019
- 2019-10-17 KR KR1020217014239A patent/KR20210081361A/ko unknown
- 2019-10-17 WO PCT/AU2019/051134 patent/WO2020077412A1/en unknown
- 2019-10-17 CN CN201980066632.9A patent/CN112867511A/zh active Pending
- 2019-10-17 MX MX2021004225A patent/MX2021004225A/es unknown
- 2019-10-17 BR BR112021007256-0A patent/BR112021007256A2/pt unknown
- 2019-10-17 AU AU2019362925A patent/AU2019362925A1/en not_active Abandoned
- 2019-10-17 US US17/285,569 patent/US20220106594A1/en not_active Abandoned
- 2019-10-17 CA CA3114945A patent/CA3114945A1/en active Pending
- 2019-10-17 JP JP2021546400A patent/JP2022508835A/ja active Pending
- 2019-10-17 EP EP19872588.9A patent/EP3866859A4/en active Pending
- 2019-10-17 SG SG11202102185RA patent/SG11202102185RA/en unknown
-
2021
- 2021-04-13 IL IL282323A patent/IL282323A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210081361A (ko) | 2021-07-01 |
EP3866859A1 (en) | 2021-08-25 |
SG11202102185RA (en) | 2021-05-28 |
CA3114945A1 (en) | 2020-04-23 |
CN112867511A (zh) | 2021-05-28 |
JP2022508835A (ja) | 2022-01-19 |
IL282323A (en) | 2021-05-31 |
AU2019362925A1 (en) | 2021-05-06 |
EP3866859A4 (en) | 2023-08-09 |
BR112021007256A2 (pt) | 2021-08-10 |
WO2020077412A1 (en) | 2020-04-23 |
US20220106594A1 (en) | 2022-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fouad et al. | Cervical sprouting of corticospinal fibers after thoracic spinal cord injury accompanies shifts in evoked motor responses | |
ES2560107T3 (es) | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF | |
AU2003293035A8 (en) | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) | |
US20150211005A1 (en) | Mirna modulators of thermogenesis | |
EP2679246A3 (en) | Novel therapeutical tools and methods for treating blindness | |
EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
PH12021551122A1 (en) | Method for treating muscular dystrophy by targeting utrophin gene | |
WO2010017248A3 (en) | Sting (stimulator of interferon genes), a regulator of innate immune responses | |
SG170819A1 (en) | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith | |
WO2010065787A3 (en) | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene | |
BR112019005548A2 (pt) | tratamento da doença de huntington com aav | |
CY1121037T1 (el) | Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
WO2007109097A3 (en) | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF | |
EP1549660A4 (en) | RNA INTERFERENCE-INHIBITING INHIBITION OF GENE EXPRESSION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) USING SMALL FRAGMENTS OF INTERFERING NUCLEIC ACIDS (SINA) | |
EP2633052A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH THE INTERFERON 1-RELATED DEVELOPMENT REGULATOR (IFRD1) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPTION PRODUCT OF IFRD1 | |
ATE528008T1 (de) | Rnai-modulation von aha und ihre therapeutische verwendung | |
RU2013102545A (ru) | Связывающая vegfa си-рнк и способы лечения in vivo | |
MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
WO2005037211A3 (en) | Methods and compositions for the treatment of neurological disease | |
MX2021014478A (es) | Metodo para tratar distrofia muscular por direccionamiento del gen dmpk. | |
MX2021004225A (es) | Metodos para tratar distrofia muscular oculofaringea (dmof). | |
EP0859636A4 (en) | HYALURONIC ACID USED AS A DNA CARRIER FOR GENE THERAPY AND ANTI-SENSE DNA OF THE VASCULAR ENDOTHELIUM GROWTH FACTOR FOR THE TREATMENT OF ABNORMAL RETINA VASCULARIZATION | |
MX2021007932A (es) | Molecula oligomerica de acido nucleico y uso de esta. | |
PH12020551191A1 (en) | Oligodendrocyte-specific promoter, mirna specific to plp1 gene, vector including said promoter and/or mirna, and pharmaceutical composition including said vector | |
DE602005026834D1 (de) | Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort |